Idexx Laboratories price target raised to $570 from $525 at Stifel

Stifel raised the firm’s price target on Idexx Laboratories to $570 from $525 and keeps a Hold rating on the shares. The company’s results and guidance “were not heroic,” argues the analyst, who contends that the move in shares is “likely all attributable to multiple expansion.” However, the firm believes shares may take a pause, even though it adds that the “components of the revenue growth algo were likely better than people expected.”